AXGN:NASDAQ
AxoGen, Inc Common Stock
$36.04
arrow_downward
-0.74%(-0.27) 1D
$35.95
arrow_downward
-0.25% (-0.090)todayPre-market
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$36.31
High
$36.88
Low
$35.82
Mkt. cap
2.11B
Avg. vol.
1.34M
Volume
116.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.17
Shares outstanding
58.67M
No. of employees
622
Open
$36.31
High
$36.88
Low
$35.82
Mkt. cap
2.11B
Avg. vol.
1.34M
Volume
116.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.17
Shares outstanding
58.67M
No. of employees
622
News stories
From web sources and news partners
MarketBeat
·
20 minutes ago
Enlight Renewable Energy (NASDAQ:ENLT) Upgraded at Zacks Research
IBS Intelligence
·
28 minutes ago
Nasdaq Ventures invests in One Trading for derivatives trading
Yahoo Finance
·
1 hour ago
Should You Invest in the Invesco S&P 500 Equal Weight Industrials ETF (RSPN)?
Bloomberg.com
·
4 hours ago
AI Bubble Risks Worst S&P 500 Crash Since 2008, Strategist Says
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com